Compare · BDX vs SIBN
BDX vs SIBN
Side-by-side comparison of Becton Dickinson and Company (BDX) and SI-BONE Inc. (SIBN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SIBN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 59.0x SIBN ($875.8M).
- Over the past year, BDX is down 2.2% and SIBN is up 19.0% - SIBN leads by 21.2 points.
- SIBN has been more active in the news (14 items in the past 4 weeks vs 10 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 12 for SIBN).
- Company
- Becton Dickinson and Company
- SI-BONE Inc.
- Price
- $189.79-0.43%
- $19.55+0.49%
- Market cap
- $51.69B
- $875.8M
- 1M return
- +19.45%
- +14.63%
- 1Y return
- -2.22%
- +18.96%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 10
- 14
- Recent ratings
- 25
- 12
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest SIBN
- SEC Form 144 filed by SI-BONE Inc.
- Chief Executive Officer Francis Laura sold $1,088,201 worth of shares (55,807 units at $19.50) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Op & Financial Officer Maheshwari Anshul sold $337,138 worth of shares (16,975 units at $19.86) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 234,920 units (SEC Form 4)
- SEC Form 144 filed by SI-BONE Inc.
- SEC Form 144 filed by SI-BONE Inc.
- Chief Executive Officer Francis Laura sold $279,065 worth of shares (14,956 units at $18.66), decreasing direct ownership by 2% to 493,900 units (SEC Form 4) (tax liability)
- SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $69,411 worth of shares (3,725 units at $18.63), decreasing direct ownership by 1% to 273,650 units (SEC Form 4) (tax liability)
- Chief Financial Officer Maheshwari Anshul sold $87,016 worth of shares (4,665 units at $18.65), decreasing direct ownership by 2% to 251,895 units (SEC Form 4) to cover withholding tax
- SEC Form SCHEDULE 13G filed by SI-BONE Inc.
- Director Dunn Jeffrey W exercised 20,000 shares at a strike of $4.68 and sold $369,214 worth of shares (20,000 units at $18.46) as part of a pre-agreed trading plan (SEC Form 4)